

Gout: Diagnosis and Management Committee meeting 5

Date: 04/01/2021

Location: Video-conference via Zoom

Minutes: Final

Committee members present:			
Aung Soe	(Present for notes 1 – 4)		
Ed Roddy	(Present for notes 1 – 4)		
Alastair Dickson	(Present for notes 1 – 4)		
Sam Finnikin	(Present for notes 1 – 4)		
Jane Taylor	(Present for notes 1 – 4)		
Sarah Ryan	(Present for notes 1 – 4)		
Hugh Gallagher	(Present for notes 1 – 4)		
Hilton Hirst	(Present for notes 1 – 4)		
Mohamed Irfaniq	(Present for notes 1 – 4)		
Lorraine Watson	(Present for notes 1 – 3a)		

In attendance:		
Clifford Middleton	Guideline Commissioning Manager, NICE	(Present for notes 1 – 4)
Ian Mather	Resource Impact, NICE	(Present for notes 1 – 4)
Amber Hernaman	Project Manager, NGC	(Present for notes 1 – 4)
Julie Neilson	Senior Reviewer, NGC	(Present for notes 1 – 4)
Gill Ritchie	Guideline Lead, NGC	(Present for notes 1 – 4)
Audrius Stonkus	Research Fellow, NGC	(Present for notes 1 – 4)
Alexandra Bonnon	Health Economist, NGC	(Present for notes 1 – 4)
Sophia Kemmis Betty	Senior Health Economist	(Present for notes 3b-d)
Judith McBride	NICE Editor	(Present for notes 1 – 4)

Apologies:	
Kelsey Jordan	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth guideline committee meeting on gout.

Lorraine Watson, Co-opted committee member specialising in dietary and lifestyle requirements for gout, introduced herself to the committee.

Hilton Hirst, newly recruited lay member introduced himself to the committee.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was

- Evidence review 5.1 Treat-to-target
- Recommendations 3.1-3-2 Pharma/non-pharma management of flares
- Health Economic Plan

Protocols:

- 4.6 Diet and lifestyle
- 4.1 Patient selection and timing for urate lowering therapy
- 6.2 Surgical excision of tophi

The Chair asked everyone to verbally declare any interests.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
Ed Roddy	Reader in Rheumatology and Honorary Consultant Rheumatologist, Keele University	A member of the independent steering committee that oversaw the conduct of the Doherty study included in the treat-to-target review. No involvement in the running of the trial and	Direct non-financial	No action needed other than process of open declaration.

		no payment received for this work.		
Alastair Dickson	GP locum, North and East Yorkshire	RCGP MSK Meeting Gout lecture covering diagnosis and management in primary care in the UK. Gave a presentation and received a fee from RCGP for presenting.	Direct Financial	No action needed other than process of open declaration.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations, questions and discussion

- a) Julie Nielsen led the discussion on the following protocols;
- 4.6 Diet and lifestyle
- 4.1 Patient selection
- 6.2 Surgical excision of tophi
- b) Audrius Stonkus presented and led the clinical discussion on the Treat-totarget evidence review and Alexandra Bonnon presented and led the health economic discussion. The committee drafted the initial recommendations
- c) Audrius Stonkus drafted the recommendations on the pharmacological/non-pharmacological management of flares
- d) Alexandra Bonnon presented and led the discussion on the health economic plan

4. Any other business

None.

Date of next meeting: 26/02/2021

Location of next meeting: Video-conference